What Bright Minds Biosciences does

Bright Minds Biosciences is a clinical-stage biotechnology company developing selective serotonergic small-molecule therapeutics for central nervous system disorders. Its lead program, BMB-101, is a 5-HT2C Gq-protein-biased agonist being developed for patients with drug-resistant absence seizures and developmental and epileptic encephalopathies (DEE). It is also advancing BMB-105 as a dedicated follow-on compound for Prader-Willi syndrome and has identified depression and other CNS disorders as additional pipeline areas.

The company describes a proprietary chemistry platform designed to produce 5-HT2A and 5-HT2C agonists without 5-HT2B activity, a selectivity profile intended to reduce cardiac valvulopathy risk. BMB-101 uses a novel biased-agonist scaffold. In January 2026, Bright Minds reported Phase 2 BREAKTHROUGH results showing a 73.1% median reduction in absence seizures and a 63.3% reduction in major motor seizures in DEE; DBA/2 mouse data reported in May 2025 indicated potential SUDEP-prevention activity, which remains preclinical evidence. Bright Minds launched the Phase 2a NOVA study for Prader-Willi syndrome in November 2025.

The company is pre-revenue and has no disclosed product sales, pricing, payer contracts, or commercial customers. Research and development is funded through equity capital; Bright Minds completed a $175.05 million public offering in January 2026 and reported CA$310 million in cash as of March 2026. It is listed on the CSE and Nasdaq under DRUG, and the supplied data do not disclose a launch schedule or commercialization model.

Name

Bright Minds Biosciences

Legal name

Bright Minds Biosciences Inc.

Website

https://brightmindsbio.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Bright Minds Biosciences is a pre-revenue, clinical-stage biotech developing selective serotonergic therapeutics for CNS disorders, led by BMB-101 for drug-resistant epilepsy and BMB-105 for Prader-Willi syndrome, with Phase 2 programs underway and equity-funded research operations.

Ownership category

akta.pro rank

Product category

Neurology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Serotonergic therapeutics
• 5-HT2 receptor agonists
• Epilepsy drug development
• Clinical-stage biopharmaceuticals
• Central nervous system therapeutics

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. No Commercial Revenue: Bright Minds Biosciences is a clinical-stage biotechnology company with no commercialized products and no revenue from product sales. The company generates no operating revenue and relies entirely on equity and debt financings to fund operations. As of March 2026, the company held CA$310 million in cash with no debt. The company reported quarterly earnings of ($0.70) per share, reflecting net losses consistent with clinical-stage biotech operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Bright Minds Biosciences is a clinical-stage biotechnology company developing a proprietary pipeline of highly selective serotonergic (5-HT2A and 5-HT2C) agonists to treat drug-resistant epilepsy, Prader-Willi Syndrome, and other central nervous system disorders. Lead candidate BMB-101 is a novel-scaffold 5-HT2C Gq-protein biased agonist designed for chronic use that demonstrated a 73.1% median reduction in absence seizures and a 63.3% median reduction in major motor seizures in the Phase 2 BREAKTHROUGH trial; follow-on compound BMB-105 is being advanced for Prader-Willi Syndrome.

Product overview

Bright Minds Biosciences is a clinical-stage biotechnology company developing a pipeline of novel compounds targeting key serotonin receptors in the brain. The company's proprietary chemistry platform has produced highly selective 5-HT2 agonists without 5-HT2B activity. The lead product BMB-101 is a 5-HT2C Gq-protein biased agonist currently in Phase 2 development for drug-resistant epilepsy (absence seizures and developmental epileptic encephalopathies), with positive Phase 2 results showing significant seizure reduction. A second compound, BMB-105, is in Phase 1 development for Prader-Willi Syndrome. The company is also preparing for global registrational trials in both DEE and Absence Seizures targeting market opportunities of $1-2 billion per indication.

Differentiator

Problem solved

Functional benefit

Products and services

• BMB-101 Novel scaffold 5-HT2C Gq-protein biased agonist developed using structure-based drug design for chronic treatment of neurological disorders; demonstrated 73.1% median reduction in absence seizures and 63.3% median reduction in major motor seizures in the Phase 2 BREAKTHROUGH trial for drug-resistant epilepsy (absence seizures and DEE including LGS, Dravet, and Rett syndrome).
• BMB-105 Dedicated follow-on 5-HT2 agonist compound entering Phase 1 clinical trials for safety and tolerability evaluation, targeting hyperphagia and behavioral symptoms in patients with Prader-Willi Syndrome.

Quantifiable outcome

• 73.1% median reduction in absence seizure ≥3s (p=0.012) and 74.4% median reduction in total time in seizures ≥3s during 24h in Phase 2 Absence Seizure cohort (n=11 evaluable patients)
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• University of Illinois at Chicago (UIC)coreStrategic or Co-development Partner · 23 April 2021Exclusive worldwide license agreement with UIC's Board of Trustees covering Patent Rights and Technical Information in all fields of use for developing products incorporating the licensed IP. The agreement includes milestone payments, net sales royalties (3-4.5%), and sublicense revenue royalties (10-12%). The company also issued 12,600 common shares and paid a signing fee of US$100,000 less US$15,000 in option fees (CDN$105,502) to UIC.

Scale indicators13 records

Expansion highlights7 records

Direct peers

• Longboard Pharmaceuticals: Longboard was developing bexicaserin, a 5-HT2C receptor agonist for developmental and epileptic encephalopathies including Dravet syndrome. Acquired by Lundbeck for $2.5B. Most directly comparable to BMB-101 due to shared 5-HT2C mechanism, epilepsy focus, and similar drug class.
• Praxis Precision Medicines: Clinical-stage biotech focused on CNS disorders including epilepsy (DEE programs such as LGS and Dravet) and rare genetic neurological diseases. Comparable in target indications, drug development stage, and small-cap biotech profile to Bright Minds.
• Marinus Pharmaceuticals: Specialty neurology company developing therapeutics for seizure disorders, including ganaxolone approved for CDKL5 deficiency disorder and studied in refractory status epilepticus. Comparable in epilepsy/rare neurology focus and clinical-stage profile.
• BioXcel Therapeutics: Clinical-stage biopharmaceutical company leveraging AI to develop neuroscience therapeutics, including approved IGALMI for agitation in schizophrenia/bipolar and BXCL501 in development for various CNS indications. Comparable small-cap CNS biotech profile.
• Axsome Therapeutics: Commercial-stage CNS-focused company with approved therapies (Auvelity for depression, Sunosi for narcolepsy) and pipeline in migraine and other neurological disorders. Comparable in CNS specialty pharma positioning, though more advanced commercially.

Emerging players

• Neumora Therapeutics: Clinical-stage neuroscience company developing precision medicines for brain diseases, with pipeline spanning depression, schizophrenia, and other CNS disorders. Comparable in CNS-focused biotech profile and recent public listing trajectory.
• Sage Therapeutics (acquired by Biogen): Recently acquired by Biogen for $7.3B; developed CNS therapeutics including Zurzuvae (with Biogen) for postpartum depression and prior epilepsy programs. Comparable in CNS specialty focus and as a recent M&A target validating CNS biotech valuations.

Broad incumbents

• Lundbeck: Global pharmaceutical company specializing in CNS disorders, with major franchises in depression, epilepsy, and neurodegeneration. Acquired Longboard for $2.5B, directly competing in 5-HT2C epilepsy space with bexicaserin. Comparable as the dominant CNS specialty pharma.
• Jazz Pharmaceuticals: Large specialty pharma with significant neurology and epilepsy franchises (Epidiolex/Epidyolex for Dravet, LGS, TSC) plus psychiatry products (Sunosi, Xywav). Comparable as an established CNS-focused player with overlapping epilepsy targets.
• UCB: Global biopharma with major neurology franchise including Vimpat, Briviact, and Fintepla for epilepsy (acquired through Zogenix acquisition). Comparable as a broad incumbent in the epilepsy specialty pharma space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/brightmindsbio
• LinkedInlinkedin.com/company/bright-minds-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bright Minds Biosciences